Results 141 to 150 of about 31,601 (273)

5PSQ-077 Bevacizumab versus biosimilar: use in ophthalmology [PDF]

, 2022
A Alcobia, Santos Domingos, C Canário, H Mestre, T Barreira, M Lobanov, Mafalda Sá Pereira, Filipe Moraes   +7 more
openalex   +1 more source

Anticipating Knowledge Applicability in Open Science Through Recycling, Mimicking, and Shortcutting

R&D Management, Volume 56, Issue 1, Page 71-87, January 2026.
ABSTRACT Open science literature scrutinizes how organizations provide access to knowledge. Yet, much less is known about how organizations pursuing open science for societal impact anticipate knowledge applicability—that shared knowledge is reusable for other organizations and individuals, and enables open social innovation.
Konstantin Hondros, Milena Leybold, Leonhard Dobusch, Sigrid Quack   +3 more
wiley   +1 more source

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Drug Design, Development and Therapy, 2017
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M   +5 more
doaj  

Biosimilars: State of Clinical and Regulatory Science

, 2017
Ágnes Klein, Jian Wang, Brian G. Feagan, Mark Omoto   +3 more
openalex   +1 more source

A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

International Journal of Women's Health, 2019
Weiguang Xue,1 Adam Lloyd,1 Edel Falla,1 Claudia Roeder,2 Rudiger Papsch,2 Klaus Bühler3,41IQVIA, Real-World Evidence, London, UK; 2Merck KGaA, Frankfurt, Germany; 3Centre for Gynecology Endocrinology & Reproductive Medicine Kinderwunsch-Zentrum
Xue W, Lloyd A, Falla E, Roeder C, Papsch R, Bühler K   +5 more
doaj  

Limited Options to Manage Specialty Drug Spending [PDF]

, 2012
Outlines rising trends in costs of and spending on specialty drugs; health plans' efforts to curb specialty drug spending, including patient cost sharing and utilization management; and efforts to integrate medical and pharmaceutical ...
Divya R. Samuel, Ha T. Tu
core  

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI) [PDF]

Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
openalex   +1 more source

Review of medicine registration system in Tanzania [PDF]

, 2019
Philosophiae Doctor - PhDRegistration of medicines is an essential function of the national medicine regulatory system of any country. Since the start of the medicine registration system in Tanzania in early 2000s, no systematic review has been carried
KISOMA, SUNDAY
core  

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

BMC Health Services Research
Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies ...
Kerry A. Ryan, Shirley Cohen-Mekelburg, Jessica A. Baker, Eileen M. Weinheimer-Haus, Chris Krenz, Jason K. Hou, Raymond De Vries, Akbar K. Waljee   +7 more
doaj   +1 more source

FDA and EMA Biosimilar Approvals [PDF]

, 2019
Emily H. Jung, Ameet Sarpatwari, Aaron S. Kesselheim, Michael S. Sinha   +3 more
openalex   +1 more source